Waters Corporation announced on May 21, 2025, that it has acquired Halo Labs™, an innovator of specialized imaging technologies. Halo Labs focuses on detecting, identifying, and counting interfering materials (particles) in therapeutic products, including cell, protein, and gene therapies.
Halo Labs' Aura™ platform offers full spectrum particle analysis, which complements Waters' existing light scattering detection solutions from its Wyatt Technology™ Portfolio. This technology provides additional insights, such as detecting translucent process impurities in CAR T-cell therapies that are often undetectable by standard methods.
This acquisition is expected to integrate emerging technology into new and existing large molecule development and QA/QC workflows, providing a key value-add to customers and accelerating Waters' growth into analytical and bioprocessing testing for large molecule therapies. The acquisition is anticipated to have a negligible impact on Waters' income statement over the subsequent 12 months.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.